TST10088

TST10088 is a recombinant variant of a plant toxin from the class II ribosome inactivating proteins, engineered as an investigational anti-cancer prodrug. It incorporates a peptide switch that is specifically cleaved by matrix metalloproteinases (MMPs), enzymes commonly upregulated in tumor growth and metastasis. Upon cleavage by MMPs within the tumor microenvironment, the prodrug becomes activated, leading to ribosomal inactivation and induction of apoptosis selectively in cancer cells while sparing healthy tissue. The drug was originally developed by Twinstrand Therapeutics and later acquired by Cangene Corporation. Its primary indication has been for neoplasms/solid tumors, with clinical development reaching Phase 1 trials[2][3][5][6].